Cobalt-labeled bleomycin: a new radiopharmaceutical for tumor localization. A comparative clinical evaluation with gallium citrate

Journal Article · Mon Sep 01 04:00:00 EDT 1975 · J. Nucl. Med., v. 16, no. 9, pp. 839-841

OSTI ID:4142852

Poulose, K P; Watkins, A E; Reba, R C; Eckelman, W C; Goodyear, M

The efficacy of $sup 57$Co-labeled bleomycin as a tumor-scanning agent was evaluated in 50 patients with malignant tumor. In terms of sensitivity, labeled bleomycin was found to be a superior agent for malignant tumor detection when compared with $sup 67$Ga-citrate. Maximum sensitivity (96 percent) was found in epidermoid carcinomas. Because of rapid blood clearance and rapid excretion by the kidneys, interpretation of $sup 57$Co-bleomycin scans is facilitated. (auth)

• Research Organization: Washington Hospital Center, Washington, DC
• NSA Number: NSA-33-001064
• OSTI ID: 4142852
• Journal Information: J. Nucl. Med., v. 16, no. 9, pp. 839-841, Journal Name: J. Nucl. Med., v. 16, no. 9, pp. 839-841; ISSN JNMEA
• Country of Publication: United States
• Language: English

Related Subjects

*COBALT 60-- DIAGNOSTIC TECHNIQUES
*GALLIUM 67-- DIAGNOSTIC TECHNIQUES
*NEOPLASMS-- DIAGNOSTIC TECHNIQUES
550601* --Biomedical Sciences
Basic Studies--Medicine-- Unsealed Radionuclides in Diagnostics
BLEOMYCIN
CITRATES
COMPARATIVE EVALUATIONS
N40420 --Chemistry--Radiochemistry & Nuclear Chemistry--Properties of Radioactive Materials
N48830* --Life Sciences--New Tracer Techniques--Other
NUCLEAR MEDICINE
PATIENTS
RADIONUCLIDE ADMINISTRATION
RADIONUCLIDE KINETICS
RADIOPHARMACEUTICALS
SCINTISCANNING